Britain and America have reached a landmark trade agreement that will preserve no levies on British medicine products going into the US market.
The Terms of the Deal
As part of the deal, the UK has pledged to increase expenditure on medicines through the public health system. This commitment ensures that duties on these key products will stay at nothing for a duration of the next three years.
This deal comes after previous statements to hike duties on patented pharmaceutical imports, with increases mentioned up to double the cost.
"This arrangement with the UK reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue balance to U.S.–U.K. medicine commerce," a statement declared.
Commercial Importance
Medicines are one of the UK's most significant export categories to the United States, which is easily the largest destination for major British pharmaceutical firms.
Trade data reveal that in the year to the end of the third quarter, the UK shipped medicines worth £11.1bn to the US. This amount accounted for 17.4% of British export trade in that span.
"This agreement safeguards jobs, boosts funding and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a minister remarked.
Key UK Commitments
The pact entails several key changes from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it deems new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to double overall public funding on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must return to the NHS to stay within budget will be limited at 15%. Previously, refunds topped 20%.
Industry Background
The pact comes amid a ongoing row between the drug companies and the British authorities over drug pricing and approval rates.
These tensions were exacerbated by claims that US consumers were charged significantly more for the identical medicines than patients in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been delayed or scrapped, while major investments have been directed toward projects in the United States.
One official stated that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had declined as a share of its total funding over the last ten years.
